GlassScriptPhysician profile
Rima El Abassi
NPI 1417143330
$305,072.67
in general payments reported to CMS, 2019-2025
31 companies · $49K in 2025
The $49K reported for 2025 was more than what 91% of Neuromuscular Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $530).
See the full distribution for Neuromuscular Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $12K · 2021: $14K · 2022: $87K · 2023: $68K · 2024: $29K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $107K · Travel and Lodging: $20K · Consulting Fee: $11K · Food and Beverage: $6,767 · Education: $53.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,055.00 |
| Travel and Lodging | $20,400.71 |
| Consulting Fee | $11,337.50 |
| Food and Beverage | $6,767.10 |
| Education | $53.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $269,304.08 | 2019-2025 | Ultomiris |
| Argenx US, INC. | $20,396.92 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Csl Behring | $6,668.37 | 2020-2025 | Hizentra |
| Ucb, INC. | $4,474.53 | 2023-2025 | Zilbrysq, Briviact, Fintepla |
| Abbvie INC. | $1,111.40 | 2022-2025 | |
| Amgen INC. | $783.95 | 2021-2025 | Uplizna, Aimovig |
| Sk Life Science, INC. | $535.33 | 2022-2025 | |
| Neurelis, INC. | $260.80 | 2022-2025 | Valtoco |
| Edw Pharma, INC. | $201.74 | 2024 | Tiglutik |
| Grifols USA, LLC | $192.41 | 2019-2023 | Gamunex-C |
| Sarepta Therapeutics, INC. | $167.61 | 2023-2024 | Exondys 51, Elevidys |
| Takeda Pharmaceuticals U.S.A., INC. | $143.84 | 2024-2025 | Hyqvia |
| Octapharma USA, INC. | $124.02 | 2023 | Panzyga |
| Eisai INC. | $103.91 | 2022-2025 | |
| Allergan, INC. | $83.51 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $78.61 | 2023 | Vyepti |
| Janssen Biotech, INC. | $65.33 | 2025 | |
| Avanir Pharmaceuticals, INC. | $61.09 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $56.93 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.36 | 2022 | |
| Pfizer INC. | $38.61 | 2024-2025 | |
| Tanabe Pharma America, INC. | $22.56 | 2025 | Radicava |
| Emd Serono, INC. | $20.64 | 2024 | |
| Medtronic USA, INC. | $18.52 | 2019 | |
| Vanda Pharmaceuticals INC. | $17.95 | 2025 | Ponvory |
| Janssen Pharmaceuticals, INC | $17.90 | 2025 | |
| Scilex Pharmaceuticals INC. | $16.15 | 2024 | |
| Itf Therapeutics LLC | $15.78 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $15.41 | 2022 | |
| Strongbridge US INC. | $12.76 | 2019 | |
| Aucta Pharmaceuticals, INC. | $7.65 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rima El Abassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.